We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+9.69%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.51B
AUM Growth
+$445M
(+8.8%)
Cap. Flow
-$338M
Cap. Flow
% of AUM
-6.13%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
167
New
43
Increased
28
Reduced
13
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$79.3M |
| 2 |
Merck
MRK
|
+$68.2M |
| 3 |
Vera Therapeutics
VERA
|
+$51.7M |
| 4 |
Legend Biotech
LEGN
|
+$39.5M |
| 5 |
Centene
CNC
|
+$30.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alignment Healthcare
ALHC
|
+$68M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$67.3M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$36.8M |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
+$32.1M |
| 5 |
InMode
INMD
|
+$28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.05% |
| 2 | Real Estate | 0.41% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Alphatec Holdings
ATEC
$1.31B
| $190K | ﹤0.01% |
+17,083
| New | +$196K |
|
102
Community Health Systems
CYH
$465M
| $189K | ﹤0.01% |
55,703
+43,986
| +375% | +$141K |
|
103
Organon & Co
OGN
$3.55B
| $159K | ﹤0.01% |
+16,388
| New | +$169K |
|
104
PACS Group
PACS
$7.3B
| $148K | ﹤0.01% |
+11,421
| New | +$119K |
|
105
10x Genomics
TXG
$5.55B
| $131K | ﹤0.01% |
11,301
-1,492,293
| -99% | -$13.6M |
|
106
Xeris Biopharma Holdings
XERS
$1.52B
| $105K | ﹤0.01% |
+22,574
| New | +$103K |
|
107
RadNet
RDNT
$4.89B
| $85.7K | ﹤0.01% |
+1,506
| New | +$82.7K |
|
|
TOIIW
108
The Oncology Institute Warrant
TOIIW
$6.21M
| $64.1K | ﹤0.01% |
1,250,000
| – | – |
|
|
NUVB.WS
109
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $45K | ﹤0.01% |
166,666
| – | – |
|
|
BFLY.WS
110
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
| $44.2K | ﹤0.01% |
733,333
| – | – |
|
111
Danaher
DHR
$144B
| $33.2K | ﹤0.01% |
+168
| New | +$32.6K |
|
112
Emergent Biosolutions
EBS
$394M
| $11.9K | ﹤0.01% |
+1,872
| New | +$10.7K |
|
113
PMV Pharmaceuticals
PMVP
$71.5M
| $9.32K | ﹤0.01% |
+8,790
| New | +$8.62K |
|
114
Charles River Laboratories
CRL
$10.8B
| $6.52K | ﹤0.01% |
+43
| New | +$5.73K |
|
115
Surrozen Inc Warrant
SRZNW
| $3.02K | ﹤0.01% |
166,666
| – | – |
|
116
Myriad Genetics
MYGN
$584M
| $2.68K | ﹤0.01% |
+505
| New | +$2.98K |
|
117
Absci
ABSI
$1.4B
| – | – |
-28,071
| Closed | -$70.5K |
|
118
Acco Brands
ACCO
$376M
| – | – |
-11,242
| Closed | -$47.1K |
|
119
Aldeyra Therapeutics
ALDX
$102M
| – | – |
-10,328
| Closed | -$59.4K |
|
120
Digital Turbine
APPS
$1.01B
| – | – |
-16,942
| Closed | -$46K |
|
121
Beam Therapeutics
BEAM
$2.83B
| – | – |
-877,809
| Closed | -$17.1M |
|
122
Butterfly Network
BFLY
$1.73B
| – | – |
-11,635
| Closed | -$26.5K |
|
123
Backblaze
BLZE
$793M
| – | – |
-21,475
| Closed | -$104K |
|
124
Perspective Therapeutics
CATX
$341M
| – | – |
-2,829,413
| Closed | -$6.03M |
|
125
C4 Therapeutics
CCCC
$408M
| – | – |
-12,528
| Closed | -$20K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2025 Portfolio in Review
As of Q2 2025, Deerfield Management held 167 positions worth $5.51B, up 8.8% from $5.06B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Deerfield Management withdrew a net $338M in Q2 2025, closing 43 positions and reducing 13 holdings. Its most notable exit was Dynavax Technologies, an estimated $67.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Deerfield Management opened a new position in Merck worth $67.9M.
- Deerfield Management's largest Q2 2025 buy was Merck: 857,724 shares worth $67.9M.
- Deerfield Management added most to United Therapeutics in Q2 2025, an estimated $79.3M increase.
- Deerfield Management's biggest Q2 2025 reduction was Alignment Healthcare, cutting an estimated $68M.
- Deerfield Management fully exited Dynavax Technologies in Q2 2025, selling an estimated $67.3M.
- Deerfield Management's ten largest holdings make up 54% of its $5.51B portfolio in Q2 2025.
- Deerfield Management opened 43 new positions and closed 43 in Q2 2025.
- Deerfield Management's portfolio value rose 8.8% quarter-over-quarter to $5.51B.
Based on Deerfield Management's 13F filing for Q2 2025, filed 14 Aug 2025.